FIELD: biochemistry.
SUBSTANCE: described is a group of inventions comprising an antibody-drug conjugate for the treatment of a tumour and/or cancer, a drug, an antitumour drug and/or an anticancer drug containing said antibody-drug conjugate, a pharmaceutical composition, a method of treating a tumour and/or cancer, a drug-linker intermediate, a linker for preparing said antibody-drug conjugate. Antibody-drug conjugate comprises an antitumour compound conjugated with the antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH-(CH2)n1-La-Lb-Lc-, where the antibody is attached to the terminal of L1, and the antitumour compound is attached to the terminal of Lc with the nitrogen atom of the amino group at position 1 as the binding site.
EFFECT: proposed invention widens the range of agents with antitumour activity.
53 cl, 22 dwg, 75 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2776489C2 |
ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 2014 |
|
RU2705367C2 |
ANTI-HER3 ANTIBODY-DRUG CONJUGATE | 2015 |
|
RU2711640C2 |
ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 2014 |
|
RU2743077C2 |
ANTI-HER2 ANTIBODY DRUG CONJUGATE | 2015 |
|
RU2794183C2 |
ANTI-HER2 ANTIBODY-DRUG CONJUGATE | 2015 |
|
RU2683780C2 |
ANTI-HER3 CONJUGATE ANTIBODY-DRUG | 2015 |
|
RU2802211C2 |
ANTI-MUC1 DRUG CONJUGATE | 2019 |
|
RU2804703C2 |
ANTI-CDH6-ANTIBODY AND ANTI-CDH6-ANTIBODY-DRUG CONJUGATE | 2018 |
|
RU2798285C2 |
ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
Authors
Dates
2018-08-17—Published
2013-10-10—Filed